imatinib mesylate has been researched along with Mast-Cell Sarcoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, H; Liu, WP; Ma, HB; Wang, YC; Xu, X; Zeng, F | 1 |
| Airley, R | 1 |
| Hioki, K; Kawabata, M; Kobie, K; Maruo, K; Matsuda, H; Mori, T; Tanaka, A | 1 |
1 trial(s) available for imatinib mesylate and Mast-Cell Sarcoma
| Article | Year |
|---|---|
The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Imatinib Mesylate; Mast-Cell Sarcoma; Mice; Mice, SCID; Piperazines; Pyrimidines; Skin Neoplasms; Specific Pathogen-Free Organisms; Statistics, Nonparametric; Xenograft Model Antitumor Assays | 2007 |
2 other study(ies) available for imatinib mesylate and Mast-Cell Sarcoma
| Article | Year |
|---|---|
Successful treatment of mast cell sarcoma of the uterus with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Genes, abl; Humans; Imatinib Mesylate; Mast-Cell Sarcoma; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome; Uterine Neoplasms | 2011 |
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome | 2012 |